GlaxoSmithKline, Third-Party Payers' Antitrust Settlement Is Approved

GlaxoSmithKline, Third-Party Payers' Antitrust Settlement Is Approved

PHILADELPHIA - A federal judge in Pennsylvania on Jan. 14 granted preliminary approval to a $21.5 million cash settlement on third-party payers' (TPP) class claims that GlaxoSmithKline PLC (GSK) engaged in a fraudulent scheme to extend patent protection for antidepressant drug Wellbutrin SR (In re Wellbutrin SR Antitrust Litigation $(All End-Payor Class Actions$), No. 04-5898, E.D. Pa.).

Find full version on lexis Advance®
Access this news story on lexis.com®